The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

被引：29

作者：

Heinrich, Daniel ^{[1
]}

Bektic, Jasmin ^{[2
]}

Bergman, Andries M. ^{[3
]}

Caffo, Orazio ^{[4
]}

Cathomas, Richard ^{[5
]}

Chi, Kim N. ^{[6
]}

Daugaard, Gedske ^{[7
]}

Keizman, Daniel ^{[8
,9
]}

Kindblom, Jon ^{[10
]}

Kramer, Gero ^{[11
]}

Olmos, David ^{[12
,13
]}

Omlin, Aurelius ^{[14
,15
]}

Sridhar, Srikala S. ^{[16
]}

Tucci, Marcello ^{[17
]}

van Oort, Inge ^{[18
]}

Nilsson, Sten ^{[19
,20
]}

机构：

[1] Akershus Univ Hosp, Dept Oncol, Lorenskog, Norway

[2] Med Univ Innsbruck, Dept Urol, Innsbruck, Austria

[3] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands

[4] Santa Chiara Hosp, Med Oncol Dept, Trento, Italy

[5] Kantonsspital Graubunden, Dept Oncol & Hematol, Chur, Switzerland

[6] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada

[7] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Copenhagen, Denmark

[8] Meir Med Ctr, Dept Oncol, Genitourinary Oncol Serv, Kefar Sava, Israel

[9] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

[10] Sahlgrens Univ Hosp, Dept Oncol, Gothenburg, Sweden

[11] Med Univ Vienna, Dept Urol, Vienna, Austria

[12] Hosp Univ Virgen Victoria & Reg Malaga, CNIO IBIMA Genitourinary Canc Unit, Med Oncol Dept, Malaga, Spain

[13] Spanish Natl Canc Res Ctr, Prostate Canc Unit, Madrid, Spain

[14] Cantonal Hosp St Gallen, Dept Oncol & Haematol, St Gallen, Switzerland

[15] Univ Hosp Berne, Dept Oncol & Haematol, Bern, Switzerland

[16] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

[17] Univ Turin, San Luigi Hosp, Dept Oncol, Med Oncol, Orbassano, Italy

[18] Radboud Univ Nijmegen, Med Ctr, Dept Urol, Nijmegen, Netherlands

[19] Karolinska Inst, Dept Oncol, Stockholm, Sweden

[20] Karolinska Univ Hosp, Stockholm, Sweden

来源：

CLINICAL GENITOURINARY CANCER | 2018年 / 16卷 / 01期

关键词：

Bone metastases; Patient selection; Targeted alpha therapy; Treatment monitoring; Treatment sequence; QUALITY-OF-LIFE; BONE METASTASES; DOUBLE-BLIND; ABIRATERONE ACETATE; SKELETAL METASTASES; INCREASED SURVIVAL; PROGNOSTIC-FACTORS; EMITTING RA-223; OPEN-LABEL; DICHLORIDE;

D O I：

10.1016/j.clgc.2017.08.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for patients treated with radium-223 and best standard of care (BSoC) when compared with placebo and BSoC in the ALpharadin in SYMptomatic Prostate CAncer (ALSYMPCA) trial. At that time, docetaxel was the standard first-line choice for patients with metastatic CRPC (mCRPC). Since then, the treatment landscape has changed dramatically with new hormonal agents (abiraterone and enzalutamide) considered to be the first-line choice for many patients. The optimal patient profile for radium-223 in the modern setting, and its best use either in sequence or in combination with other approved agents are unclear, with few definitive guidelines available. This article reports on the views of a group of urologists and medical oncologists experienced in treating patients with mCRPC with radium-223 in routine clinical practice. The aim is to provide an overview of the current use of radium-223 in the treatment of patients with mCRPC, and to discuss best practices for patient selection and on-treatment monitoring. Where agreement was reached, guidance on the optimal use of radium-223 is provided. (C) 2017 The Authors. Published by Elsevier Inc.

引用

页码：E223 / E231

页数：9

共 63 条

[1] Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer [J].